Our results indicate a presurgical SRL therapy interplay with TICs in somatotroph adenomas and show that the CD68+/CD8+ ratio is a biomarker for treatment resistance in SRL‐naïve patients. Here, CD8A is linked to familial isolated pituitary adenoma.